Glow Lifetech Advances National Expansion Strategy with Quebec Commercial Partnership
Toronto, Ontario--(Newsfile Corp. - July 13, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce it has entered into an exclusive Quebec sales, distribution and licensing agreement with Les Cultures Seaweed Gaspésie Inc. ("Seaweed Cannabis"), establishing the commercial infrastructure to support the commercialization of Glow's MOD™ and .decimal™ brands in Quebec. The partnership represents another im
2026-07-13 7:30 AM EDT | Glow Lifetech Corp.
Rejuvenate Muscle Health(TM) Expands its Position in the Emerging GLP-1 Muscle Health Category with U.S. Pharmacy Program and National E-Commerce Expansion
Burlington, Ontario--(Newsfile Corp. - July 13, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") a muscle health company with distributi
Food / Beverages, Sports, Health
2026-07-13 7:00 AM EDT | Promino Nutritional Sciences, Inc.
WELL Health Announces Pricing of $150 Million Senior Unsecured Notes Offering
WELL has priced its inaugural offering of $150 million of senior unsecured notes due 2031, bearing interest at 6.875% per annum. Net proceeds will be used to fully repay WELL's convertible debentures due December 2026 and for general corporate purposes. The Offering extends WELL's debt maturity profile to 2031 and strengthens the Company's balance sheet to support continued growth in Canada. All amounts in
Technology, Computer Software, Healthcare and Hospitals, Health
2026-07-13 6:30 AM EDT | WELL Health Technologies Corp.
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - July 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company issued common shares ("Common Shares") in satisfaction of the accrued interest payable on June 30, 2026. The Notes were issued as a result of an extension to the promissory notes th
2026-07-10 7:13 PM EDT | Rapid Dose Therapeutics Corp.
NU-Med Plus Announces Acquisition of Avid Gold and Agreement to Acquire Canadian Gold Properties
United Kingdom and Vancouver, British Columbia--(Newsfile Corp. - July 10, 2026) - Nu-Med Plus, Inc. (OTCQB: NUMD) ("Nu-Med" or the "Company"), a Utah company whose shares are quoted on the OTCQB Venture Market, today announces that it has acquired Avid Gold Ltd ("Avid Gold") and its wholly-owned subsidiary Maritimes Gold Corp. ("Maritimes Gold"), a Canadian gold exploration and development company. The Company also announced today that Nu-Med and its subsidia
2026-07-10 4:15 PM EDT | Nu-Med Plus, Inc.
TelyRx Holdings Inc. Announces DTC Eligibility for U.S. Traded Shares
Clearwater, Florida--(Newsfile Corp. - July 10, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a digital healthcare and online pharmacy platform, today announced that its subordinate voting shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company ("DTC"). DTC eligibility is expected to simplify trading, improvement settlement efficiency, and enhance the liquidity a
Healthcare and Hospitals, Health
2026-07-10 7:00 AM EDT | TelyRx
DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx(TM) Red Eye and Quantitative ELISA Testing
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx™ Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026. Interim results were obtained and analyzed from 30 tear samples originating
2026-07-09 8:30 AM EDT | DiagnosTear Technologies Inc.
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee. Mr. LaRocca is a three-decade biopharmaceutical in
2026-07-09 8:00 AM EDT | BetterLife Pharma Inc.
Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review
Winter Park, Florida--(Newsfile Corp. - July 9, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA) announced today that FINRA has processed its corporate name change to Adia Med Inc. on an expedited timeline. The name change will be reflected on the FINRA Daily List today, with trading under the new name expected to begin tomorrow, Friday, July 10, 2026, on the OTC Markets.
Healthcare and Hospitals, Health
2026-07-09 8:00 AM EDT | Adia Med Inc.
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
Highlights Meuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel's four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured
Technology, Biotechnology, Pharmaceuticals, Health
2026-07-09 7:00 AM EDT | TempraMed Technologies Ltd.
Rise Nano Optics Announces First U.S. Eye Care Professional Partnership with LI Opticians
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, today announced its first U.S. eye care professional (ECP) partnership with LI Opticians, an independent optical practice located in Seaford, New York, owned and operated by Barry Santini, a contributing editor to Lenses & Technolo
2026-07-09 12:15 AM EDT | Rise Nano Optics Ltd.
TelyRx to Present at the Global Technology Virtual Investor Conference July 9, 2026
Clearwater, Florida--(Newsfile Corp. - July 8, 2026) - Hot on the heels of its one million prescriptions filled milestone, TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a technology-enabled healthcare and online pharmacy platform focused on expanding access to FDA-approved medications across the United States, announced today that Vanessa Slowey, President and Chief Executive Officer, and John Cascio, Chief Financial Officer, will present live at t
Healthcare and Hospitals, Health
2026-07-08 1:05 PM EDT | TelyRx
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Biotechnology, Pharmaceuticals, Health
2026-07-08 10:08 AM EDT | Hemostemix Inc.
Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg
Toronto, Ontario--(Newsfile Corp. - July 8, 2026) -
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-07-08 8:00 AM EDT | Rhelion Life Sciences Corp.
Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update on its forward-looking product development and segment expansion roadmap for its wholly owned subsidiary, Holy Crap Foods Inc. Following the Company's recent disclosure of its preliminary June 2026 financial growth highlights, management is working to build upon this operational trajectory b
Technology, Biotechnology, Health
2026-07-08 6:00 AM EDT | Restart Life Sciences Corp.
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development a
Biotechnology, Pharmaceuticals, Health
2026-07-08 3:15 AM EDT | Defence Therapeutics Inc.
Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.
Winter Park, Florida--(Newsfile Corp. - July 7, 2026) - Adia Nutrition Inc. (OTCQB: ADIA) today announced it has entered the final stage of its corporate name change application from Adia Nutrition Inc. to Adia Med Inc. After several months of review by the Financial Industry Regulatory Authority (FINRA), including three rounds of comments and the submission of detailed supporting documentation, the Company believes it has now met all outstanding requirements. FINRA approval is anticipated wi
Healthcare and Hospitals, Health
2026-07-07 10:19 AM EDT | Adia Med Inc.
Tersis Technologies Appoints Cynthia Maloney as Vice President of Strategic Grants & Public-Private Partnerships
Brooksville, Florida--(Newsfile Corp. - July 7, 2026) - Tersis Technologies, Inc. (OTCID: TERS), a clean technology company focused on transforming waste streams into valuable resources through advanced thermal conversion, carbon utilization, renewable energy, and sustainable infrastructure solutions, today announced the appointment of Cynthia Maloney as Vice President, Strategic Grants & Public-Private Partnerships.
Agriculture, Energy, Alternative Energy, Health
2026-07-07 9:38 AM EDT | Tersis Technologies Inc.
ALST Health Brands Signs Memorandum of Understanding to Produce "Beyond the Game Network" Reality Soccer Series
Toronto, Ontario--(Newsfile Corp. - July 7, 2026) - ALST Health Brands (OTCID: ALST) today announced the execution of a Memorandum of Understanding (MOU) to develop and produce a new reality soccer series, "Beyond the Game Network." The agreement formalizes a strategic partnership to create original unscripted content that highlights player journeys, community impact, and the intersection of sport, health, and culture. Key elements of the MOU:
Healthcare and Hospitals, Retail, Health
2026-07-07 8:16 AM EDT | AllStar Health Brands, Inc.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre
Toronto, Ontario--(Newsfile Corp. - July 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-07-07 8:12 AM EDT | Rhelion Life Sciences Corp.